• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Blue Gold Appoints Quazar's Sameer Salgar to Advisory Board to Establish UAE Ties and Guide Digital Gold Strategy

    9/10/25 9:40:00 AM ET
    $BGL
    $NTHI
    Metal Mining
    Basic Materials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BGL alert in real time by email

    NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Blue Gold Limited (NASDAQ:BGL) ("Blue Gold" or the "Company"), a next-generation gold development and technology company, today announced the appointment of Sameer Salgar, Founding Partner and Chief Financial Officer of Quazar Investment, to its Advisory Board.

    Sameer brings over 20 years of investment, corporate finance, and strategic advisory experience. As co-founder of Quazar Investment, a UAE-based private investment firm, he has built a reputation for leading transformational cross-border transactions and connecting growth companies with global capital partners. His addition to the Advisory Board underscores Blue Gold's commitment to scaling its acquisition strategy, expanding its digital gold platform, and establishing ties to the UAE, one of the world's fast-growing financial centers.

    As Advisory Board member, Sameer and Quazar will:

    • Guide the rollout of digital technology solutions aligned with Blue Gold's Digital Gold Initiative.
    • Assist with the establishment of UAE-based gold deposit and vaulting infrastructure, enhancing security and scalability.
    • Facilitate introductions to regional capital providers, strengthening Blue Gold's access to growth funding and institutional partnerships.

    "I am excited to join Blue Gold's Advisory Board at such a pivotal time," said Sameer Salgar. "The Company's vision of combining world-class gold assets with innovative digital technologies aligns perfectly with Quazar's focus on global growth opportunities."

    Quazar Investment has advised on and participated in several high-profile international transactions, including its advisory participation in an $8 billion all-cash bid for Citgo Refining, a downstream energy asset, as well as a $50 million strategic partnership with NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) during its Nasdaq uplisting.

    "We are honored to welcome Sameer to Blue Gold's Advisory Board," said Andrew Cavaghan, Chief Executive Officer of Blue Gold. "As a seasoned executive and visionary business leader, he has consistently delivered on high-profile deals and demonstrated a deep understanding of capital markets. His experience and global network will add tremendous value as we scale our mining acquisitions and advance our Digital Gold Initiative."

    Gold remains a cornerstone of global finance, and demand for gold-backed digital products continues to expand. By combining real mining assets with a tokenized gold platform, Blue Gold aims to deliver shareholder growth while addressing the global need for secure, asset-backed digital currencies. The appointment of Sameer to the Advisory Board strengthens this vision, providing deal-making expertise and strategic UAE market connectivity.

    About Quazar Investment

    Quazar Investment, headquartered in the United Arab Emirates, is a private investment firm specializing in energy, infrastructure, and capital markets. Quazar has advised on high-profile international transactions, including major energy asset bids and advisory mandates for Nasdaq-listed companies. Leveraging its global network and strong presence in the UAE, Quazar helps companies access capital, technology, and market opportunities across key growth sectors.

    About Blue Gold Limited

    Blue Gold Limited (NASDAQ:BGL) is a next-generation gold development company focused on acquiring and aggregating high-potential mining assets across strategic global jurisdictions. The Company's mission is to unlock untapped value in the gold sector by combining disciplined resource acquisition with innovative monetization models, including asset-backed digital instruments. Blue Gold is committed to responsible development, operational transparency, and leveraging modern financial technologies to redefine how gold is produced, accessed, and owned in the 21st century.

    Blue Gold prioritizes growth, sustainable development, and transparency in all our business practices. We believe that our commitment to responsible mining will enable us to create value for our shareholders while minimizing our environmental footprint.



    Forward-Looking Statements

    This press release includes "forward-looking statements" within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements include, but are not limited to: general economic or political conditions; negative economic conditions that could impact Blue Gold Limited and the gold industry in general; reduction in demand for Blue Gold Limited's products; changes in the markets that Blue Gold Limited targets; and any change in laws applicable to Blue Gold Limited or any regulatory or judicial interpretation.  As a result, we cannot assure you that the forward-looking statements included in this press release will prove to be accurate or correct. These and other important factors and risks are discussed in Blue Gold Limited's shell company report on Form 20-F, filed with the U.S. Securities and Exchange Commission (the "SEC") on July 1, 2025, and other filings with the SEC.  In light of these risks, uncertainties, and assumptions, the future performance or events described in the forward-looking statements in this press release might not occur. Accordingly, you should not rely upon forward-looking statements as a prediction of actual results, and we do not assume any responsibility for the accuracy or completeness of any of these forward-looking statements. Except as required by applicable law, we do not undertake any obligation to, and will not, update any forward-looking statements, whether as a result of new information, future events, or otherwise. For more information regarding Blue Gold Limited, please visit https://bluegoldmine.com.

    No Offer or Solicitation

    This press release shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed business combination. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption.

    For Further Information Contact:

    Tavistock Communications

    [email protected]

    +44 20 7920 3150

    Skyline Corporate Communications Group, LLC

    Scott Powell, President

    1177 Avenue of the Americas, 5th Floor

    New York, NY. 10036

    Office: (646) 893-5835

    Email: [email protected]



    Primary Logo

    Get the next $BGL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BGL
    $NTHI

    CompanyDatePrice TargetRatingAnalyst
    More analyst ratings

    $BGL
    $NTHI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Puri Ishwar Kanwar

    3 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    9/5/25 8:53:58 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Clinical Officer Neman-Ebrahim Yousha was granted 133,000 shares (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    6/9/25 7:40:19 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Neman-Ebrahim Yousha

    3 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    6/9/25 7:35:23 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BGL
    $NTHI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President Heshmatpour Amir F bought $14,785 worth of CommonStock (2,000 units at $7.39), increasing direct ownership by 0.11% to 1,762,000 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    5/23/25 9:31:11 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Chen Thomas C bought $40,002 worth of shares (5,468 units at $7.32), increasing direct ownership by 1% to 551,668 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    5/23/25 9:30:24 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO Garnett Keithly bought $4,921 worth of shares (675 units at $7.29), increasing direct ownership by 0.28% to 240,900 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    5/23/25 9:28:12 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BGL
    $NTHI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42's IROS and Expands Board of Directors

    CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 09, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, has announced two major strategic developments that solidify its expansion into the Middle East. Its wholly owned subsidiary, NuroMENA Holdings Ltd., has signed a Master Services Agreement (MSA) with Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, part of the M42 group — a global health company powered by Artificial Intelligence (AI), technology and genomics. In a con

    10/9/25 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies and Quazar Investment Set to Close $50 Million Strategic Partnership by October 23rd Following Final UAE Tax Approvals

    CALABASAS, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced a significant milestone in its partnership with Quazar Investment. Following the receipt of all necessary tax identification and regulatory approvals from the United Arab Emirates (UAE), the closing of the previously announced $50 million strategic partnership is mandated to occur no later than October 23rd, 2025, as stipulated by the definitive signed agreement. The finalization of these administrative requirements in the UAE official

    10/6/25 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies Appoints Dr. David M. Ashley, Director of The Preston Robert Tisch Brain Tumor Center at Duke, to Scientific Advisory Board

    CALABASAS, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced it has appointed Dr. David M. Ashley to its scientific advisory board. Dr. Ashley is the Rory David Deutsch Distinguished Professor of Neuro-Oncology and the Director of The Preston Robert Tisch Brain Tumor Center at Duke University. Amir F. Heshmatpour, Executive Chairman & President, of NeOnc Technologies, commented, "We are privileged to have Dr. David M. Ashley MBBS (Hons), FRACP, PhD, of Duke University on NeOnc's Scientific Adv

    10/2/25 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BGL
    $NTHI
    SEC Filings

    View All

    Amendment: SEC Form F-1/A filed by Blue Gold Limited

    F-1/A - Blue Gold Ltd (0002019435) (Filer)

    10/21/25 5:16:29 PM ET
    $BGL
    Metal Mining
    Basic Materials

    Amendment: SEC Form F-1/A filed by Blue Gold Limited

    F-1/A - Blue Gold Ltd (0002019435) (Filer)

    10/21/25 5:11:28 PM ET
    $BGL
    Metal Mining
    Basic Materials

    SEC Form POS AM filed by Blue Gold Limited

    POS AM - Blue Gold Ltd (0002019435) (Filer)

    10/21/25 5:08:48 PM ET
    $BGL
    Metal Mining
    Basic Materials

    $BGL
    $NTHI
    Leadership Updates

    Live Leadership Updates

    View All

    NeOnc Technologies Appoints Dr. David M. Ashley, Director of The Preston Robert Tisch Brain Tumor Center at Duke, to Scientific Advisory Board

    CALABASAS, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced it has appointed Dr. David M. Ashley to its scientific advisory board. Dr. Ashley is the Rory David Deutsch Distinguished Professor of Neuro-Oncology and the Director of The Preston Robert Tisch Brain Tumor Center at Duke University. Amir F. Heshmatpour, Executive Chairman & President, of NeOnc Technologies, commented, "We are privileged to have Dr. David M. Ashley MBBS (Hons), FRACP, PhD, of Duke University on NeOnc's Scientific Adv

    10/2/25 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies Welcomes Dr. Alexandra M. Miller, Chief of Neuro-Oncology and Co-Director of the Brain and Spine Tumor Center at NYU Langone Health's Perlmutter Cancer Center, to Its Scientific Advisory Board

    CALABASAS, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced the appointment of Dr. Alexandra M. Miller to its scientific advisory board. Dr. Miller is the Chief of the Neuro-oncology Program and Co-Director of the Brain and Spine Tumor Center at NYU Langone Health's Perlmutter Cancer Center, where she specializes in treating patients with primary brain tumors. "We are thrilled to welcome Dr. Alexandra Miller to our Scientific Advisory Board," said Amir F. Heshmatpour, Executive Chairman and P

    10/1/25 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board

    CALABASAS, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced it has appointed Dr. Henry S. Friedman to its scientific advisory board. Dr. Friedman is an internationally renowned academic adult and pediatric neuro-oncologist who helps to lead The Preston Robert Tisch Brain Tumor Center at Duke University. He is the author of more than 500 peer reviewed articles, reviews, and book chapters and has presented extensively at both international and national meetings. "We are incredibly ho

    9/29/25 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care